More focus is being directed toward indirect targeting and drug combinations, such as improving enzalutamide efficacy in CRPC by inhibiting KIF4A [5], or overcoming chemoresistance in CRC with oxaliplatin and 5-FU10,43. Here, KIF4A is linked to colorectal carcinoma.